Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema

References

• SmithWAssinkJKleinRRisk factors for age-related macular degeneration: pooled findings from three continentsOphthalmology2001108469770411297486
   PubMed Web of Science ®Google Scholar
• CheungCMTaiESKawasakiRPrevalenec of and risk factors for age-related macular degeneration in a multiethnic Asian cohortArch Ophthalmol2012130448048622159171
   PubMedGoogle Scholar
• KleinRKleinBEKnudtsonMDMeuerSMSwiftMGangnonREFifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye StudyOphthalmology2007114225326217270675
   PubMed Web of Science ®Google Scholar
• WongTYChakravarthyUKleinRThe natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysisOphthalmology2008115111612617675159
   PubMed Web of Science ®Google Scholar
• FerraraNDamicoLShamsNLowmanHKimRDevelopment of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degenerationRetina200626885987017031284
   PubMed Web of Science ®Google Scholar
• LopezPFSippyBDLambertHMTransdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranesInvest Ophthalmol Vis Sci19963758558688603870
   PubMed Web of Science ®Google Scholar
• DonosoLAKimDFrostAThe role of inflammation in the pathogenesis of age-related macular degenerationSurv Ophthalmol200651213715216500214
   PubMed Web of Science ®Google Scholar
• ChanWMLaiTYTanoYLiuDTLiKKLamDSPhotodynamic therapy in macular diseases of asian populations: when East meets WestJpn J Ophthalmol200650216116916604394
   PubMed Web of Science ®Google Scholar
• BresslerNMPhotodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2Arch Ophthalmol2001119219820711176980
   PubMed Web of Science ®Google Scholar
• BresslerNMVerteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2Am J Ophthalmol2002133116816911755871
   PubMed Web of Science ®Google Scholar
• BrownDMMichelsMKaiserPKHeierJSSyJPIanchulevTRanibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR studyOphthalmology200911615765e5519118696
   PubMed Web of Science ®Google Scholar
• RosenfieldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
   PubMed Web of Science ®Google Scholar
• RegilloCDBrownDMAbrahamPRandomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1Am J Ophthalmol2008145223924818222192
   PubMed Web of Science ®Google Scholar
• LalwaniGARosenfieldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO StudyAm J Ophthalmol20091481435819376495
   PubMed Web of Science ®Google Scholar
• HolzFGAmoakuWDonateJSafety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN studyOphthalmology2011118466367121459217
   PubMed Web of Science ®Google Scholar
• SingerMAAwhCCSaddaSHORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degenerationOphthalmology201211961175118322306121
   PubMed Web of Science ®Google Scholar
• CATT Research GroupMartinDFMaguireMGRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
   PubMed Web of Science ®Google Scholar
• ChakravarthyUHardingSPRogersCARanibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trialOphthalmology201211971399141122578446
   PubMed Web of Science ®Google Scholar
• YauJWRogersSLKawasakiRGlobal prevalence and major risk factors of diabetic retinopathyDiabetes Care201235355656422301125
   PubMed Web of Science ®Google Scholar
• CheungNMitchellPWongTYDiabetic retinopathyLancet2010376973512413620580421
   PubMed Web of Science ®Google Scholar
• Photocoagulation for diabetic macular edemaEarly Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research groupArch Ophthalmol198510312179618062866759
   PubMedGoogle Scholar
• GroverDLiTJChongCCIntravitreal steroids for macular edema in diabetesCochrane Database Syst Rev20081CD00565618254088
   PubMed Web of Science ®Google Scholar
• DoDVNguyenQDKhwajaAARanibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatmentArch Ophthalmol20131312139145
   Google Scholar
• NguyenQDBrownDMMarcusDMRanibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDEOphthalmology2012119478980122330964
   PubMed Web of Science ®Google Scholar
• NguyenQDShahSMHeierJSPrimary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) studyOphthalmology2009116112175218119700194
   PubMed Web of Science ®Google Scholar
• NguyenQDShahSMKhwajaAATwo-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) studyOphthalmology2010117112146215120855114
   PubMed Web of Science ®Google Scholar
• MassinPBandelloFGarwegJGSafety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II studyDiabetes Care201033112399240520980427
   PubMed Web of Science ®Google Scholar
• MitchellPBandelloFSchmidt-ErfurthUThe RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edemaOphthalmology2011118461562521459215
   PubMed Web of Science ®Google Scholar
• ElmanMJQinHAielloLPIntravitreal ranibizumab for diabetic Macular edema with prompt versus deferred laser treatment: three-year randomized trial resultsOphthalmology2012119112312231822999634
   PubMed Web of Science ®Google Scholar
• FerraraNVascular endothelial growth factor: basic science and clinical progressEndocr Rev200425458161115294883
   PubMed Web of Science ®Google Scholar
• StewartMWThe expanding role of vascular endothelial growth factor inhibitors in ophthalmologyMayo Clin Proc2012871778822212972
   PubMed Web of Science ®Google Scholar
• GragoudasESAdamisAPCunninghamETJrFeinsodMGuyerDRVEGF Inhibition Study in Ocular Neovascularization Clinical Trial Groupfor neovascular age-related macular degenerationN Engl J Med2004351272805281615625332
   PubMed Web of Science ®Google Scholar
• BlickSKKeatingGMWagstaffAJRanibizumabDrugs20076781199120617521219
   PubMed Web of Science ®Google Scholar
• KimKJLiBWinerJInhibition of vascular endothlial growth factor-induced angiogenesis suppresses tumor growth in vivoNature199336264238418447683111
   PubMed Web of Science ®Google Scholar
• PrestaLGChenHO’ConnorSJHumanization of an anti-VEGF monoclonal antibody for the therapy of solid tumours and other disordersCancer Res19975720459345999377574
   PubMed Web of Science ®Google Scholar
• FerraraNKerbelRSAngiogenesis as a therapeutic agentNature2005438707096797416355214
   PubMed Web of Science ®Google Scholar
• FramptonJERanibizumab: in diabetic macular oedemaDrugs201272450952322356289
   PubMed Web of Science ®Google Scholar
• LoweJAraujoJYangJRanibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivoExp Eye Res200785442543017714704
   PubMed Web of Science ®Google Scholar
• GaudreaultJFeiDRusitJSubocPShiuVPreclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administrationInvest Ophthalmol Vis Sci200546272673315671306
   PubMed Web of Science ®Google Scholar
• GaudreaultJFeiDBeyerJCPharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbitsRetina20072791260126618046235
   PubMed Web of Science ®Google Scholar
• KrohneTULiuZHolzFGMeyerCHIntraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humansAm J Ophthalmol2012154468268622818800
   PubMed Web of Science ®Google Scholar
• XuLLuTTuomiLPharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration – a population approachInvest Ophthalmol Vis Sci20135431616162423361508
   PubMed Web of Science ®Google Scholar
• BoyerDSHeierJSBrownDMFrancomSFIanchulevTRubioRGA Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovacsular age-related macular degenerationOphthalmology200911691731173919643495
   PubMed Web of Science ®Google Scholar
• MartinDFMaguireMGFineSLRanibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year resultsOphthalmology201211971388139822555112
   PubMed Web of Science ®Google Scholar
• SchmuckerCEhlkenCAgostiniHTA safety review and meta-analyses of bevaizumab and ranibizumab: off-label versus gold standardPLoS ONE201278e4270122880086
   PubMed Web of Science ®Google Scholar
• MitchellPRESTORE extension study group2-year safety and efficacy outcome of ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema (DME): an interim analysis of the RESTORE extension studyInvest Ophthalmol Vis Sci201253 ARVO E-abstract 4667
   Google Scholar
• OhjiMIshibashiTREVEAL study groupEfficacy and safety of ranibizumab 0.5 mg as monotherapy or adjunctive to laser versus laser monotherapy in Asian patients with visual impairment due to diabetic macular edema: 12-month results of the REVEAL studyInvest Ophthalmol Vis Sci201253 ARVO E-abstract 4664
   Google Scholar
• ElmanMJAielloLPBeckRWRandomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edemaOphthalmology2010117610641077e103520427088
   PubMed Web of Science ®Google Scholar
• ElmanMJBresslerNMQinHExpanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edemaOphthalmology2011118460961421459214
   PubMed Web of Science ®Google Scholar
• MitchellPAnnemansLWhiteRGallagherMThomasSCost effectiveness of treatments for wet age-related macular degenerationPharmacoeconomics201129210713121244102
   PubMed Web of Science ®Google Scholar
• ColquittJLJonesJTanSCTakedaACleggAJPriceARanibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluationHealth Technol Assess20081216iiiivix20118462575
   PubMed Web of Science ®Google Scholar
• NeubauerASHolzFGSauerSCost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: model analysis from the perspective of Germany’s statutory health insurance systemClin Ther20103271343135620678682
   PubMed Web of Science ®Google Scholar
• MitchellPAnnemansLGallagherMCost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trialBr J Ophthalmol201296568869322399690
   PubMed Web of Science ®Google Scholar
• BresslerNMChangTSFineJTDolanCMWardJImproved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trialArch Ophthalmol20091271132119139332
   PubMedGoogle Scholar
• BresslerNMChangTSSunerIJVision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOROphthalmology2010117474775620189654
   PubMed Web of Science ®Google Scholar
• BresslerNMChangTSVarmaRDriving ability reported by beovascular age-related macular degeneration patients after treatment with ranibizumabOphthalmology2013120116016823009891
   PubMed Web of Science ®Google Scholar
• FrennessonCNilssonULPeeboBBNilssonSESignificant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degenerationActa Ophthalmol201088442042519678811
   PubMed Web of Science ®Google Scholar
• BandelloFHolzFGGilliesMCKohAMitchellPLUMINOUS groupSafety, efficacy, treatment patterns of ranibizumab therapy for neovascular age-related macular degneration: the LUMINOUS studiesInvest Ophthalmol Vis Sci201253 ARVO E-abstract 2031
   Google Scholar
• HeierJSBrownDMChongVIntravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
   PubMed Web of Science ®Google Scholar
• ChaikitmongkolVBresslerNMDramatic resolution of choroidal neovascular abnormalities after single aflibercept injection following years of ranibizumab useJAMA Ophthalmol2013131226026223411901
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyEylea: EPAR – public assessment report. EMA/646256/2012 corr9202012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002392/WC500135744.pdfAccessed April 17, 2013
   Google Scholar